NEW from NCI Minute: ComboMatch

Learn more about ComboMATCH: the new clinical trial initiative to evaluate combinations of treatments that block both the drivers of tumor growth and the mechanisms of resistance.

The primary goal for ComboMATCH is to see whether the use of drug combinations can overcome the resistance to treatment that can arise with the use of a single drug that targets a genetic change. Each drug combination tested in ComboMATCH was selected based on strong evidence of its promise to improve patient outcomes.

ComboMATCH is supported by NCI and is coordinated by the ECOG-ACRIN Cancer Research GroupExit Disclaimer. Personnel from NCI, ECOG-ACRIN, and the other U.S. trial groups in NCI’s National Clinical Trials Network (NCTN)—the Alliance for Clinical Trials in OncologyExit Disclaimer, NRG Oncology GroupExit Disclaimer, the SWOG Cancer Research NetworkExit Disclaimer, and the Children’s Oncology GroupExit Disclaimer— collaborated to develop ComboMATCH.

To learn more about ComboMATCH or to see if you or a loved one is eligible to enroll visit: